Journal of Clinical Oncology
Articles in this Issue
Prognostic impact of SMARCA4 deficiency and STK11 co-mutations on non-small cell lung cancer treated with immune checkpoint inhibitors.
e20511 Background: SMARCA4/BRG1-deficient non-small cell lung cancer (SD-NSCLC) is highly aggressive and has a poor prognosis. The efficacy of immune chec...
Neoadjuvant chemoradiotherapy plus PD-1 inhibitor (tislelizumab) for high risk and MRF+ low locally advanced rectal cancer.
e15644 Background: PD-1 inhibitors combined with chemoradiotherapy have shown preliminary efficacy in the neoadjuvant treatment of MSS rectal cancer, incl...
Exploring tumor genomics and clinical outcomes in in adolescent and young adult (AYA) breast cancer.
567 Background: Breast cancer in adolescents and young adults (AYAs, defined as individuals aged 39 or younger) often exhibits aggressive biological behav...
Immune landscape of liver metastases in advanced lung cancer.
8540 Background: The liver is a frequent site of metastasis and carries a poor prognosis in patients with non-small cell (NSCLC) and small cell lung cance...
Risk of death, thrombotic, and hemorrhagic events in anticoagulated patients with atrial fibrillation and hepatocellular carcinoma: An analysis from a global federated dataset.
e16250 Background: Atrial fibrillation (AF) is a prevalent arrhythmia associated with increased thrombotic and hemorrhagic risks, necessitating anticoagul...
Evaluating the efficiency and quality of clinical summaries produced by a large language model (LLM).
e13601 Background: The critical task of curating data from various sources into an accurate and concise summary can be tedious, time-consuming, and error-...
Efficacy and safety profile of spinal laser interstitial thermal therapy for metastatic spinal cord compression.
e14657 Background: Metastatic epidural spinal cord compression (MESCC) is a condition where tumor growth encroaches the spinal cord, leading to neurologic...
AI-driven biomarker prediction in oncology: Enhancing pathological image analysis with EXAONEPath.
2592 Background: Hematoxylin and eosin (H&E)-stained whole-slide images (WSIs) are fundamental in cancer diagnosis, providing critical insights into t...
Identifying physician perspectives of facilitators and barriers in clinical trial accrual to inform implementation strategies for advancing equitable enrollment in a large comprehensive cancer center.
e23030 Background: While robust infrastructure is established to support high quality clinical trials at USC Norris Comprehensive Cancer Center (NCCC), im...
Exploring contemporary trends in diagnosis, stage and treatment outcomes for upper tract urothelial cancer (UTUC) and non-urothelial cancer (nUC) upper tract: A National Cancer Database (NCDB) analysis.
e16558 Background: Upper tract cancers (UTC) make up a rare population of genitourinary tumors that tends to be more aggressive in presentation. Histologi...
Concordance of response-based clinical trial and machine learning–generated real-world end points.
e13625 Background: Real-world evidence (RWE) is increasingly used to complement clinical trial data in oncology, providing rapid insights to inform study...
Radio-genomics analysis of contrast-enhanced MRI for predicting therapeutic response to lenvatinib-based systemic therapy in hepatocellular carcinoma.
e16325 Background: Systemic therapies, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), are vital for treating unresec...
Epidemiology of <i>MET</i> gene mRNA expression in metastatic colorectal cancer: Analyses of a real-world clinicogenomic database.
10562 Background: The MET proto-oncogene encodes the c-Met protein and is associated with promotion of tumor growth, angiogenesis,...
Predictors of post-transplant survival in patients with newly diagnosed acute myeloid leukemia receiving frontline venetoclax and hypomethylating agents.
e18523 Background: Allogeneic hematopoietic stem cell transplant (AHCT) remains the only curative option for genetically high-risk acute myeloid leukemia...
Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic (PD) markers and tumor gene expression by mevrometostat in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC).
e17032 Background: Mevrometostat (M) is a potent and selective small molecule inhibitor of EZH2. Dose exploration of M in combination with enzalutamide (E...
Digital spatial profiling of advanced solid tumors and lymphomas from a phase 1 trial of copanlisib and nivolumab.
3127 Background: Digital spatial profiling (DSP) is an innovative technique that facilitates spatially resolved proteotranscriptomic analysis within tissu...
Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216).
e17109 Background: With significant advancements in treatments over the past decade, there is a growing need to identify biomarkers that facilitate person...
Neutrophil-to-lymphocyte ratio as a clinical biomarker for immune checkpoint inhibitor response in advanced sarcoma.
11543 Background: As immunotherapy gains traction in sarcoma treatment, identifying biomarkers and understanding patterns of response to immune checkpoint...
The future is here now: Use of proteomic testing in pulmonary nodule management in an underserved population in Brooklyn, NY.
e22513 Background: NodifyLung proteomic testing is designed to help risk stratify low to moderate risk pulmonary nodules characterized by 5-65% risk of ma...
Factors associated with occurrence of acute leukemias and myelodyplastic neoplasms as seen at the Kenyatta National Hospital, Nairobi, Kenya.
e18502 Background: Acute leukaemias-acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) usually carry poor prognosis. Myelodysplastic ne...
A multivariate model to predict delay in diagnosis and treatment of breast cancer in Pakistan: A retrospective cohort study.
e13175 Background: The mortality of breast cancer (BC) is significantly increased by delays in diagnosis and treatment. This study aimed to investigate th...
Baseline autoimmune diseases and characteristics of solid tumor patients on immune checkpoint inhibitor (ICI) therapy enrolled in a prospective study of immune-related adverse events (irAEs): SWOG S2013 (I-CHECKIT).
2600 Background: I-CHECKIT is a prospective observational study whose primary objective is to develop and independently validate a risk prediction model f...
Integrating deep proteomics into precision oncology for multi-omics characterization of metastatic cancer.
e15065 Background: Precision oncology is enhancing cancer treatment by tailoring therapies to specific genetic and molecular profiles. However, identifyin...
Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer: Initial results of the FIERCE study.
3602 Background: Total neoadjuvant therapy (TNT) with chemo-radiation (CRT) followed by doublet chemotherapy for rectal cancer can yield clinical complete...
Racial/ethnic disparities in neoplasm mortality and the role of healthcare access in the United States: Insights from the Global Burden of Disease study study 2000–2019.
e13738 Background: Persistent racial/ethnic and regional disparities in neoplasm mortality remain significant public health challenges. This study evaluat...